Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats.
In ordder to evaluate 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) as a possible antithrombotic compound, a simple and reproducible method for experimental thrombosis in rats was devised. A silken thread was inserted in the extracorporeal shunt between the carotid artery and the jugular vein. 15 min after the circulation of blood, wet weight of thrombus which developed on the thread was measured to determine the degree and rate of thrombus formation. Equalization of average body weight of rats for each group provided good reproducibility. Microscopic examination demonstrated that the thrombus was primarily composed of platelets. By use of the technique, the activities of KC-6141 and two known inhbitors, aspirin and dipyridamole, were determined. Of the three compounds, KC-6141 was the most potent inhibitor for the thrombosis. Its ED50 was 60 mg/kg when given orally and the compound was activite for about 40 hr. Aspirin was about twice as less active than KC-6141 and dipyridamole showed no effect on the thrombosis. The ranking order of potency against the experimental thrombosis for the three compounds was the same as that for inhibition of platelet aggregation in vitro and platelet retention in rats, as reported previously by us. Therefore the method seems to be associated with platelet aggregation and retention. The above result suggests that KC-6141 is of value as antithrombotic drug in vivo.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D013927:Thrombosis / Q000188:drug therapy*
D007093:Imidazoles; D011725:Pyridines; C016861:1-methyl-2-mercapto-5-(3-pyridyl)imidazole; D004176:Dipyridamole; D001241:Aspirin